Kymab: Sanofi completes Kymab acquisition

Sanofi announced today the successful completion of its acquisition of Kymab Group Ltd., adding KY1005 to its pipeline, a fully human monoclonal antibody targeting key immune system regulator OX40L. The acquisition continues to build on Sanofi's leading presence in immunology aligned with the company's strategy to pursue best-in-class treatments in defined areas. Kymab's pipeline also includes the oncology asset KY1044, an ICOS agonist monoclonal antibody, currently in early Phase1/...